A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects

Molecular and Cellular Endocrinology

Volumn 160, Issue 1-2, 2000, Pages 39-49

  Térouanne, Béatrice ^a   Tahiri, Bouchra ^a   Georget, Virginie ^a   Belon, Charles ^b   Poujol, Nicolas ^a   Avances, Christophe ^a,c   Orio Jr , Francesco ^b   Balaguer, Patrick ^a   Sultan, Charles ^a,b  

^a INSERM   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antiandrogen; Human androgen receptor; PC 3 cells; Prostate cancer; Stable transfectant

Indexed keywords

17BETA HYDROXY 2,2,17ALPHA TRIMETHYLESTRA 4,9,11 TRIEN 3 ONE; ALDOSTERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DEXAMETHASONE; ESTRADIOL; HYDROCORTISONE; HYDROXYFLUTAMIDE; INOCOTERONE ACETATE; LUCIFERASE; METRIBOLONE; MIFEPRISTONE; NEOMYCIN; NILUTAMIDE; PARTIAL AGONIST; PROGESTERONE; PROMEGESTONE; PUROMYCIN; SPIRONOLACTONE; TESTOSTERONE; UNCLASSIFIED DRUG;

AGONIST; ARTICLE; BIOLUMINESCENCE; CELL CLONE; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; DRUG SELECTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HORMONE BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; REPORTER GENE; TIME; TRANSACTIVATION; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; ANDROGENS; CELL DIVISION; CELL LINE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GENES, REPORTER; HUMANS; KINETICS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MAMMARY TUMOR VIRUS, MOUSE; PROSTATE; RECEPTORS, ANDROGEN; STEROIDS; TRANSFECTION;

EID: 0343851745     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(99)00251-8     Document Type: Article

References (34)

1. Battmann T., Branche C., Bouchoux F., Cerede E., Philibert D., Goubet F., Teutsch G., GaillardKelly M. Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders. J. Steroid Biochem. Mol. Biol. 64:1998;103-111.
2. Beck C.A., Weigel N.L., Moyer M.L., Nordeen S.K., Edwards D.P. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Natl. Acad. Sci. USA. 90:1993;4441-4445.
3. Berrevoets C.A., Doesburg P., Steketee K., Trapman J., Brinkmann A.O. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol. Endocrinol. 12:1998;1172-1183.
4. Berrevoets C.A., Veldscholte J., Mulder E. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J. Steroid Biochem. Mol. Biol. 46:1993;731-736.
5. Boudon C., Lobaccaro J.M., Lumbroso S., Lechevallier E., Mottet N., Gibelin B., Sultan C. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates - effect of finasteride (Proscar), a 5 α-reductase inhibitor. Cell. Mol. Biol. (Noisy-le-grand). 41:1995;1007-1015.
6. Brass A.L., Barnard J., Patai B.L., Salvi D., Rukstalis D.B. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res. 55:1995;3197-3203.
7. Castagnetta L., Granata O.M., Polito L., Blasi L., Cannella S., Carruba G. Different conversion metabolic rates of testosterone are associated to hormone-sensitive status and -response of human prostate cancer cells. J. Steroid Biochem. Mol. Biol. 49:1994;351-357.
8. Castagnetta L.A., Carruba G., Traina A., Granata O.M., Markus M., Pavone-Macaluso M., Blomquist C.H., Adamski J. Expression of different 17β-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells. Endocrinology. 138:1997;4876-4882.
9. Deslypere J.P., Young M., Wilson J.D., McPhaul M.J. Testosterone and 5 α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol. Cell. Endocrinol. 88:1992;15-22.
10. Fuhrmann U., Bengtson C., Repenthin G., Schillinger E. Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of CAT expression by anti-androgens. J. Steroid Biochem. Mol. Biol. 42:1992;787-793.
11. Georget V., Terouanne B., Lumbroso S., Nicolas J.C., Sultan C. Trafficking of androgen receptor mutants fused to green fluorescent protein: a new investigation of partial androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 83:1998;3597-3603.
12. Gray L.E. Jr Tiered screening and testing strategy for xenoestrogens and antiandrogens. Toxicol. Lett. 102-103:1998;677-680.
13. Heisler L.E., Evangelou A., Lew A.M., Trachtenberg J., Elsholtz H.P., Brown T.J. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol. Cell. Endocrinol. 126:1997;59-73.
14. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37:1980;115-132.
15. Kelce W.R., Monosson E., Gamcsik M.P., Laws S.C., Gray L.E. Jr Environmental hormone disruptors: evidence that vinclozolin developmental toxicity is mediated by antiandrogenic metabolites. Toxicol. Appl. Pharmacol. 126:1994;276-285.
16. Kelce W.R., Wilson E.M. Environmental antiandrogens: developmental effects, molecular mechanisms, and clinical implications. J. Mol. Med. 75:1997;198-207.
17. Kemppainen J.A., Lane M.V., Sar M., Wilson E.M. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J. Biol. Chem. 267:1992;968-974.
18. Kemppainen J.A., Langley E., Wong C.I., Bobseine K., Kelce W.R., Wilson E.M. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol. Endocrinol. 13:1999;440-454.
19. Kuil C.W., Mulder E. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens. Endocrinology. 137:1996;1870-1877.
20. Kushner P.J., Hort E., Shine J., Baxter J.D., Greene G.L. Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol. Endocrinol. 4:1990;1465-1473.
21. Lobaccaro J.M., Poujol N., Terouanne B., Georget V., Fabre S., Lumbroso S., Sultan C. Transcriptional interferences between normal or mutant androgen receptors and the activator protein 1 - dissection of the androgen receptor functional domains. Endocrinology. 140:1999;350-357.
22. Marcelli M., Haidacher S.J., Plymate S.R., Birnbaum R.S. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid [published erratum appears in Endocrinology 1995 May, 136 (5), 2319]. Endocrinology. 136:1995;1040-1048.
23. Miyamoto H., Yeh S., Lardy H., Messing E., Chang C. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc. Natl. Acad. Sci. USA. 95:1998;11083-11088.
24. Pons M., Gagne D., Nicolas J.C., Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques. 9:1990;450-459.
25. Reyes-Moreno C., Frenette G., Boulanger J., Lavergne E., Govindan M.V., Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate. 26:1995;260-269.
26. Simard, J., Singh, S.M., Labrie, F., 1997. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Urology 49, 580-586; discussion 586-589.
27. Szelei J., Jimenez J., Soto A.M., Luizzi M.F., Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 138:1997;1406-1412.
28. Tilley W.D., Wilson C.M., Marcelli M., McPhaul M.J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 50:1990;5382-5386.
29. Toppari J., Skakkebaek N.E. Sexual differentiation and environmental endocrine disrupters. Baillieres Clin. Endocrinol. Metab. 12:1998;143-156.
30. Tovar A., Sanchez-Capelo A., Galindo J.D., Cremades A., Penafiel R. Antiandrogenic effect of RU-486 in the mouse kidney. Int. J. Biochem. Cell. Biol. 29:1997;361-366.
31. van Laar J.H., Voorhost-Ogink M.M., Zegers N.D., Boersma W.J.A., Claassen E., van der Korput J.A.G.M., Ruizeveld de Winter J.A., Van der Kwast T.H., Mulder E., Trapman J., Brinkmann A.O. Characterization of polyclonal antibodies against the N-terminal domain of the human androgen receptor. Mol. Cell. Endocrinol. 67:1989;29-38.
32. Veldscholte J., Berrevoets C.A., Brinkmann A.O., Grootegoed J.A., Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry. 31:1992;2393-2399.
33. Wong C., Kelce W.R., Sar M., Wilson E.M. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J. Biol. Chem. 270:1995;19998-20003.
34. Yuan S., Trachtenberg J., Mills G.B., Brown T.J., Xu F., Keating A. Androgen-induced inhibition of cell proliferation in an androgen- insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA [published erratum appears in Cancer Res. 1995 Feb 1, 55 (3), 719]. Cancer Res. 53:1993;1304-1311.